TAMOXIFEN AS RISK FACTOR FOR CARCINOMA OF CORPUS UTERI-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

TAMOXIFEN AS RISK FACTOR FOR CARCINOMA OF CORPUS UTERI

Published:1988-09 Issue:8610 Volume:332 Page:563
ISSN:0140-6736
Container-title:The Lancet
language:en
Short-container-title:The Lancet

Author:

Hardell Lennart

Publisher

Elsevier BV

Subject

General Medicine

Reference3 articles.

1. Contrasting actions of tamoxifen on endometrial and breast tumor growth in the athymic mouse;Gottardis;Cancer Res,1988

2. Endometrial adenocarcinoma in breast cancer patients receiving antiestrogens;Killackey;Cancer Treat Rep,1985

3. Uterine corpus;de Waard,1982

Cited by 104 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The good, the bad and the ugly of tamoxifen at Wisconsin;Tamoxifen Tales;2022

2. Selective estrogen receptor modulators and bone health;Climacteric;2021-06-25

3. A Novel Strategy to Improve Women’s Health: Selective Estrogen Receptor Modulators;Estrogen Receptor and Breast Cancer;2018-10-17

4. Inducing or Preventing Subsequent Malignancies for Breast Cancer Survivors? Double-edged Sword of Estrogen Receptor and Progesterone Receptor;Clinical Breast Cancer;2018-10

5. Epidemiology of Endometrial Carcinoma: Etiologic Importance of Hormonal and Metabolic Influences;Advances in Experimental Medicine and Biology;2016-12-02

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP